Custom Vault Corporation

Rating: 0 - Write A Review
4 Research Drive
Bethel, CT 06801
About Custom Vault Corporation
  • DEA Validated (21CFR 1301.72) modular vault systems for secure storage of Schedule I and II controlled substances are complemented by safes for smaller quantities, wire cages for Schedule III, IV and V; pallet rack solutions for inventory management and ThermaSure Chambers for temperature control. Electronic security equipment - video surveillance, intrusion alarm and access control – also available.
Competitors of Custom Vault Corporation
  • Natoli Engineering Company, Inc.

    Natoli Engineering Company, long recognized as the global leader in tablet compression tooling manufacturing, was founded on the uncompromising principle to provide the highest quality tablet compression tooling, presses, and replacement parts at a fair price with exceptional customer service.... Read More
  • Wilson Tool International

    Wilson Tool provides the most comprehensive line of tooling systems and accessories for the Tableting, Additive, Stamping, Bending and Punching industries. As the world’s largest and only tooling provider to manufacture tooling solutions for these five industries, Wilson Tool is uniquely... Read More
  • Biofluid Focus Inc.

    Biofluid Focus specializes in supplying ultra-clean, single-use bottle & carboys for biotech/bioprocessing applications. Products include sterile PharmaTainer Carboys & Bottles in PET and PC in sizes up to 20L; autoclavable PFA and FEP bottles up to 2L. The products offered reduce operating... Read More
Products by Custom Vault Corporation
  • Modular Vault Solutions

    CustomVault modular options for 21 CFR 1301.72 Schedule I-II compliance include the LightWeight™, MegaVault™ and HighBay™ Vault. Notably, the CustomVault HighBay™ Vault system compensates for restricted footprints by leveraging vertical space to accommodate controlled substance storage needs. Read more
  • Security Cages

    CustomVault designs and installs wire cage solutions that meet or exceed requirements dictated by DEA Specification 21 CFR 1301.72 for Schedule III-V pharmaceuticals. Read more